hFmiPS2
KSCBi002-B-1
General
Cell Line |
|
| hPSCreg name | KSCBi002-B-1 |
| Cite as: | KSCBi002-B-1 (RRID:CVCL_IT65) |
| Alternative name(s) |
hFmiPS2
|
| Cell line type | Human induced pluripotent stem cell (hiPSC) |
| Similar lines |
KSCBi002-B (hFmiPS1) KSCBi002-A (hFSiPS1) |
| Last update | 22nd May 2019 |
| User feedback | |
Provider |
|
| Generator | National Stem Cell Bank (KSCB) |
External Databases |
|
| BioSamples | SAMEA104012355 |
| Cellosaurus | CVCL_IT65 |
| Wikidata | Q54900500 |
General Information |
|
| Publications | |
| * Is the cell line readily obtainable for third parties? |
Yes Research use: allowed
Clinical use: not allowed
Commercial use: not allowed
|
| Subclone of | |
Donor Information
General Donor Information |
|
| Sex | male |
| Ethnicity | N/A |
Phenotype and Disease related information (Donor) |
|
| Diseases | No disease was diagnosed.
|
| Family history | N/A |
| Is the medical history available upon request? | N/A |
| Is clinical information available? | N/A |
Other Genotyping (Donor) |
|
| Is there genome-wide genotyping or functional data available? |
No
|
Donor Relations |
|
| Other cell lines of this donor | |
External Databases (Donor) |
|
| BioSamples | SAMEA104012353 |
Ethics
Also have a look at the ethics information for the parental line
KSCBi002-B
.
| Alternatives to consent | |
| For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used? | |
| Constraints for use or distribution |
hIPSC Derivation
General |
|
|
The source cell information can be found in the parental cell line
KSCBi002-B.
|
|
Reprogramming method |
|
| Vector type | Non-integrating |
| Vector | modified RNA |
| Genes | |
| Is reprogramming vector detectable? |
No |
| Methods used |
Immunostaining, PCR, RT-PCR
|
Vector free reprogramming |
|
| Type of used vector free reprogramming factor(s) |
mRNA
|
| mRNA | |
Other |
|
| Selection criteria for clones | under the checking of cell morphology by phase contrast microscopy |
| Derived under xeno-free conditions |
No |
| Derived under GMP? |
No |
| Available as clinical grade? |
No |
Culture Conditions
| Surface coating | Gelatin | ||||||||||||
| Feeder cells |
STO |
||||||||||||
| Passage method |
Enzymatically
Dispase
|
||||||||||||
| CO2 Concentration | 5 % | ||||||||||||
| Medium |
Other medium:
Base medium: DMEM/F12
Main protein source: Knock-out serum replacement Serum concentration: 20 % Supplements
|
||||||||||||
| Has Rock inhibitor (Y27632) been used at passage previously with this cell line? | No |
||||||||||||
| Has Rock inhibitor (Y27632) been used at cryo previously with this cell line? | No |
||||||||||||
| Has Rock inhibitor (Y27632) been used at thaw previously with this cell line? | Yes |
Characterisation
Analysis of Undifferentiated Cells
| Marker | Expressed | Immunostaining | RT-PCR | Flow Cytometry | Enzymatic Assay | Expression Profiles |
| POU5F1 (OCT-4) |
Yes |
|
||||
| SSEA-4 |
Yes |
|
||||
| TRA 1-60 |
Yes |
|
||||
| TRA 1-81 |
Yes |
|
Differentiation Potency
Genotyping
Karyotyping (Cell Line) |
|
| Has the cell line karyotype been analysed? |
Yes
46,XY
Passage number: p29
Karyotyping method:
G-Banding
|
Other Genotyping (Cell Line) |
|
Login to share your feedback, experiences or results with the research community.